Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avacincaptad pegol - IVERIC bio

Drug Profile

Avacincaptad pegol - IVERIC bio

Alternative Names: Anti-C5 aptamer; ARC-187; ARC-1905; Avacincaptad pegol sodium; Zimura

Latest Information Update: 01 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Archemix Corporation
  • Developer IVERIC bio
  • Class Eye disorder therapies; Oligonucleotides; Polyethylene glycols
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry age-related macular degeneration; Polypoidal choroidal vasculopathy; Stargardt disease; Wet age-related macular degeneration

Most Recent Events

  • 28 Oct 2019 Safety and efficacy data from a phase IIb trial for Dry age-related macular degeneration released by IVERIC bio
  • 16 Apr 2019 Ophthotech Corporation is now called IVERIC bio
  • 01 Feb 2019 IVERIC bio completes enrolment in the phase IIb trials in Stargardt disease 1 in USA (Intravitreous) (NCT03364153)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top